Published in Curr Opin Infect Dis on February 01, 2012
Viral diagnostics in the era of digital polymerase chain reaction. Diagn Microbiol Infect Dis (2012) 1.72
Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA. PLoS One (2014) 1.40
Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology (2013) 1.37
Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL. PLoS One (2012) 1.10
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. J Neurovirol (2016) 1.08
Nef Is Dispensable for Resistance of Simian Immunodeficiency Virus-Infected Macrophages to CD8+ T Cell Killing. J Virol (2015) 0.87
Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. AIDS Res Hum Retroviruses (2014) 0.87
Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation. J Biol Chem (2014) 0.84
Choice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cells. Mol Cell Ther (2014) 0.81
CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. Cytokine (2016) 0.80
Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study. PLoS One (2015) 0.78
HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels. World J AIDS (2013) 0.77
Pokeweed antiviral protein alters splicing of HIV-1 RNAs, resulting in reduced virus production. RNA (2014) 0.76
Barriers to a cure for HIV in women. J Int AIDS Soc (2016) 0.75
A Case of Long-Term Seronegative Human Immunodeficiency Virus (HIV) Infection: The Importance of the Humoral Response to HIV. Open Forum Infect Dis (2015) 0.75
Full Viral Suppression, Low-Level Viremia, and Quantifiable Plasma HIV-RNA at the End of Pregnancy in HIV-Infected Women on Antiretroviral Treatment. AIDS Res Hum Retroviruses (2015) 0.75
Relevance of retrovirus quantification in cerebrospinal fluid for neurologic diagnosis. J Biomed Sci (2015) 0.75
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc (2010) 1.87
Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis (2012) 1.76
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ (2012) 1.71
Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother (2007) 1.70
Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. J Infect (2010) 1.49
Travel-associated acquisition of hepatitis C virus infection in patients receiving haemodialysis. Nephrol Dial Transplant (2007) 1.41
Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother (2007) 1.16
Comparative evaluation of the ExaVir Load version 3 reverse transcriptase assay for measurement of human immunodeficiency virus type 1 plasma load. J Clin Microbiol (2009) 1.15
Evidence for onward transmission of HIV-1 non-B subtype strains in the United Kingdom. J Acquir Immune Defic Syndr (2006) 1.14
Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother (2009) 1.11
HIV phylogenetics. BMJ (2007) 1.07
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS (2007) 1.07
Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. J Clin Microbiol (2013) 1.06
Herpes simplex virus type 2 (HSV-2) seroprevalence at the time of HIV-1 diagnosis and seroincidence after HIV-1 diagnosis in an ethnically diverse cohort of HIV-1-infected persons. Sex Transm Dis (2006) 1.03
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother (2011) 1.01
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS (2010) 1.01
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr (2010) 0.99
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med (2013) 0.98
Genotypic tropism testing: evidence-based or leap of faith? AIDS (2011) 0.97
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis (2012) 0.97
Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol (2007) 0.95
Development of a real-time multiplex RSV detection assay for difficult respiratory samples, using ultrasone waves and MNAzyme technology. J Clin Virol (2009) 0.93
Interactions and management issues in HSV and HIV coinfection. Expert Rev Anti Infect Ther (2007) 0.92
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. J Antimicrob Chemother (2010) 0.91
Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience. Antiviral Res (2011) 0.88
Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load. Intervirology (2012) 0.87
Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. J Antimicrob Chemother (2010) 0.87
Comparative evaluation of the Artus HIV-1 QS-RGQ assay and the Abbott RealTime HIV-1 assay for the quantification of HIV-1 RNA in plasma. J Clin Virol (2013) 0.86
Science in court: the myth of HIV fingerprinting. Lancet Infect Dis (2011) 0.85
Disseminated neonatal herpes simplex virus (HSV) type 2 infection diagnosed by HSV DNA detection in blood and successfully managed by liver transplantation. Eur J Pediatr (2004) 0.82
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther (2011) 0.81
Reconstitution of herpes simplex virus-specific T cell immunity in HIV-infected patients receiving highly active antiretroviral therapy. J Infect Dis (2006) 0.80
Human T-cell lymphotropic virus antibody prevalence in HIV-1-infected individuals attending a sexual health clinic in South-East London. J Med Virol (2005) 0.79
Performance of a nurse-led paediatric point of care service for respiratory syncytial virus testing in secondary care. J Infect (2010) 0.78
Detecting HIV-1 superinfection by pol gene population sequencing among untreated HIV-1-infected men who experience sudden rises in plasma HIV-1 RNA load. AIDS (2011) 0.77
Antiretroviral resistance. J HIV Ther (2006) 0.76
Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza A H1N1 pandemic in London: a case-control study. BMJ Open (2013) 0.76
Missed opportunities: Undiagnosed HIV infection in patients with viral hepatitis. BMJ (2008) 0.75
Detection and typing of herpes simplex DNA in genital swabs by real-time polymerase chain reaction. J Virol Methods (2005) 0.75
Predicting antiretroviral drug resistance from the latest or the cumulative genotype. Antivir Ther (2011) 0.75
The expanding role of common respiratory viruses in human disease. J Med Microbiol (2003) 0.75
Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Antivir Ther (2008) 0.75
Immunization of the HIV infected traveller. AIDS (2007) 0.75
Primary antiretroviral resistance in newly diagnosed patients with established heterosexually acquired HIV-1. AIDS (2002) 0.75
Forgotten, but not gone. BMJ (2010) 0.75
High levels of discordance between sequencing and serological subtyping in a predominantly non-B subtype HIV-1 infected cohort. J Clin Virol (2005) 0.75
Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. J Antimicrob Chemother (2008) 0.75
Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy. J Antimicrob Chemother (2007) 0.75
New horizons in antiretroviral drug resistance. J HIV Ther (2007) 0.75